Review



fas fasl signaling antagonist  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    MedChemExpress fas fasl signaling antagonist
    Associations of CD8 + TIL subsets with (DN) TILs and clinical outcome (A) Dot color represents the communication probability of the specific ligand-receptor pairs, including TGF-β, IL-10, <t>and</t> <t>Fas-FasL</t> signaling between the indicated sender cluster and receiver clusters. (B) Representative histograms and statistical graph showing carboxyfluorescein succinimidyl ester (CFSE) dilution (left) and proliferation inhibition rates (right) of (DN) TILs with CD4 + and CD8 + naive T cells at a ratio of 4:1, 2:1, 1:1, and 1:2. The data are presented as mean ± SD, and three biological replicates were included. (C) Representative histograms and statistical graph showing CFSE dilution (left) and proliferation inhibition rates (right) of (DN) TILs with CD4 + and CD8 + naive T cells at a 1:1 ratio with neutralizing antibodies against TGF-β and IL-10, as well as the presence or absence of a Fas-FasL signaling antagonist. The data are presented as mean ± SD, and three biological replicates were included. p values were evaluated by t test (two-sided). ∗∗ p < 0.01; ∗∗∗ p < 0.001. (D) Bubble plot showing the correlation between the frequency of (DN) TILs and other TIL subsets in TIL infusion products ( n = 26). p values were determined by Spearman correlation analysis. ∗ p < 0.05. (E) Dot plot showing the correlation between the frequency of (DN) TILs and CD8 + TILs in TIL infusion products ( n = 26). p values were determined by Spearman correlation analysis. (F) Representative histograms and statistical graph showing CFSE dilution (left) and proliferation inhibition rates (right) of (DN) TILs with autologous expanded CD8 + TILs at ratios of 4:1, 2:1, and 1:1. Conventional CD4 + (i)Tregs were included as a control. The data are presented as mean ± SD, and three biological replicates were included. (G–K) Kaplan-Meier survival curves of PFS and OS in NPC patients stratified according to the abundance (high vs. low) of total CD8 + TILs (G), C2_proliferation_CD8_T_cells-PCNA (H), C4_MHC_II_CD8_T_cells (I), C6_proliferation_CD8_T_cells-TOP2A (J), and C12_tissue_resident_memory_CD8_T_cells (K) inferred from (sc)RNA sequencing data ( n = 26). p values were determined based on the two-sided log rank test. See also and .
    Fas Fasl Signaling Antagonist, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-p10102/Kp7-6/pmc12147895-345-33-38
    Average 93 stars, based on 2 article reviews
    fas fasl signaling antagonist - by Bioz Stars, 2026-10
    93/100 stars

    Images

    1) Product Images from "Tumor-infiltrated double-negative regulatory T cells predict outcome of T cell-based immunotherapy in nasopharyngeal carcinoma"

    Article Title: Tumor-infiltrated double-negative regulatory T cells predict outcome of T cell-based immunotherapy in nasopharyngeal carcinoma

    Journal: Cell Reports Medicine

    doi: 10.1016/j.xcrm.2025.102096

    Associations of CD8 + TIL subsets with (DN) TILs and clinical outcome (A) Dot color represents the communication probability of the specific ligand-receptor pairs, including TGF-β, IL-10, and Fas-FasL signaling between the indicated sender cluster and receiver clusters. (B) Representative histograms and statistical graph showing carboxyfluorescein succinimidyl ester (CFSE) dilution (left) and proliferation inhibition rates (right) of (DN) TILs with CD4 + and CD8 + naive T cells at a ratio of 4:1, 2:1, 1:1, and 1:2. The data are presented as mean ± SD, and three biological replicates were included. (C) Representative histograms and statistical graph showing CFSE dilution (left) and proliferation inhibition rates (right) of (DN) TILs with CD4 + and CD8 + naive T cells at a 1:1 ratio with neutralizing antibodies against TGF-β and IL-10, as well as the presence or absence of a Fas-FasL signaling antagonist. The data are presented as mean ± SD, and three biological replicates were included. p values were evaluated by t test (two-sided). ∗∗ p < 0.01; ∗∗∗ p < 0.001. (D) Bubble plot showing the correlation between the frequency of (DN) TILs and other TIL subsets in TIL infusion products ( n = 26). p values were determined by Spearman correlation analysis. ∗ p < 0.05. (E) Dot plot showing the correlation between the frequency of (DN) TILs and CD8 + TILs in TIL infusion products ( n = 26). p values were determined by Spearman correlation analysis. (F) Representative histograms and statistical graph showing CFSE dilution (left) and proliferation inhibition rates (right) of (DN) TILs with autologous expanded CD8 + TILs at ratios of 4:1, 2:1, and 1:1. Conventional CD4 + (i)Tregs were included as a control. The data are presented as mean ± SD, and three biological replicates were included. (G–K) Kaplan-Meier survival curves of PFS and OS in NPC patients stratified according to the abundance (high vs. low) of total CD8 + TILs (G), C2_proliferation_CD8_T_cells-PCNA (H), C4_MHC_II_CD8_T_cells (I), C6_proliferation_CD8_T_cells-TOP2A (J), and C12_tissue_resident_memory_CD8_T_cells (K) inferred from (sc)RNA sequencing data ( n = 26). p values were determined based on the two-sided log rank test. See also and .
    Figure Legend Snippet: Associations of CD8 + TIL subsets with (DN) TILs and clinical outcome (A) Dot color represents the communication probability of the specific ligand-receptor pairs, including TGF-β, IL-10, and Fas-FasL signaling between the indicated sender cluster and receiver clusters. (B) Representative histograms and statistical graph showing carboxyfluorescein succinimidyl ester (CFSE) dilution (left) and proliferation inhibition rates (right) of (DN) TILs with CD4 + and CD8 + naive T cells at a ratio of 4:1, 2:1, 1:1, and 1:2. The data are presented as mean ± SD, and three biological replicates were included. (C) Representative histograms and statistical graph showing CFSE dilution (left) and proliferation inhibition rates (right) of (DN) TILs with CD4 + and CD8 + naive T cells at a 1:1 ratio with neutralizing antibodies against TGF-β and IL-10, as well as the presence or absence of a Fas-FasL signaling antagonist. The data are presented as mean ± SD, and three biological replicates were included. p values were evaluated by t test (two-sided). ∗∗ p < 0.01; ∗∗∗ p < 0.001. (D) Bubble plot showing the correlation between the frequency of (DN) TILs and other TIL subsets in TIL infusion products ( n = 26). p values were determined by Spearman correlation analysis. ∗ p < 0.05. (E) Dot plot showing the correlation between the frequency of (DN) TILs and CD8 + TILs in TIL infusion products ( n = 26). p values were determined by Spearman correlation analysis. (F) Representative histograms and statistical graph showing CFSE dilution (left) and proliferation inhibition rates (right) of (DN) TILs with autologous expanded CD8 + TILs at ratios of 4:1, 2:1, and 1:1. Conventional CD4 + (i)Tregs were included as a control. The data are presented as mean ± SD, and three biological replicates were included. (G–K) Kaplan-Meier survival curves of PFS and OS in NPC patients stratified according to the abundance (high vs. low) of total CD8 + TILs (G), C2_proliferation_CD8_T_cells-PCNA (H), C4_MHC_II_CD8_T_cells (I), C6_proliferation_CD8_T_cells-TOP2A (J), and C12_tissue_resident_memory_CD8_T_cells (K) inferred from (sc)RNA sequencing data ( n = 26). p values were determined based on the two-sided log rank test. See also and .

    Techniques Used: Inhibition, Control, RNA Sequencing

    Related Articles

    Blocking Assay:

    Article Title: ACSS2/AATF Drives Soluble FasL-Mediated CD8 + T Cell Apoptosis in Pancreatic Neuroendocrine Tumors.
    Article Snippet: Advanced Science published by Wiley-VCH GmbH iley.com /doi/10.1002/advs.202506883 by loki revolution - U niversity Federal D e Sao Paulo , W iley O nline L ibrary on [14/10/2025]. .. See the T erm s and C onditions (https://onlinelibrary.w iley.com /term s-and-conditions) on W iley O nline L ibrary for rules of use; O A articles are governed by the applicable C reative C om m ons L icense www.advancedsciencenews.com www.advancedscience.com acetate (S8750, Sigma–Aldrich), ACSS2 inhibitor (ACSS2i, vy-3135, #1824637-41-3, MedChemExpress), FasL blocking antibody (FasL antibody) (ab186671), animal-free recombinant human soluble Fas ligand (rh-sFasL, HY-P700052AF, MedChemExpress), and Kp7-6 (HY-P10102, MedChemExpress) follow the manufacturer’s instructions. .. Positive clones were selected in puromycin (Gibco)-containing medium.

    Article Title: ACSS2/AATF Drives Soluble FasL‐Mediated CD8 + T Cell Apoptosis in Pancreatic Neuroendocrine Tumors
    Article Snippet: .. Dimethyl sulfoxide (DMSO, D2650, Sigma–Aldrich), acetate (S8750, Sigma–Aldrich), ACSS2 inhibitor (ACSS2i, vy‐3‐135, #1824637‐41‐3, MedChemExpress), FasL blocking antibody (FasL antibody) (ab186671), animal‐free recombinant human soluble Fas ligand (rh‐sFasL, HY‐P700052AF, MedChemExpress), and Kp7‐6 (HY‐ P10102 , MedChemExpress) follow the manufacturer's instructions. .. Positive clones were selected in puromycin (Gibco)‐containing medium.

    Recombinant:

    Article Title: ACSS2/AATF Drives Soluble FasL-Mediated CD8 + T Cell Apoptosis in Pancreatic Neuroendocrine Tumors.
    Article Snippet: Advanced Science published by Wiley-VCH GmbH iley.com /doi/10.1002/advs.202506883 by loki revolution - U niversity Federal D e Sao Paulo , W iley O nline L ibrary on [14/10/2025]. .. See the T erm s and C onditions (https://onlinelibrary.w iley.com /term s-and-conditions) on W iley O nline L ibrary for rules of use; O A articles are governed by the applicable C reative C om m ons L icense www.advancedsciencenews.com www.advancedscience.com acetate (S8750, Sigma–Aldrich), ACSS2 inhibitor (ACSS2i, vy-3135, #1824637-41-3, MedChemExpress), FasL blocking antibody (FasL antibody) (ab186671), animal-free recombinant human soluble Fas ligand (rh-sFasL, HY-P700052AF, MedChemExpress), and Kp7-6 (HY-P10102, MedChemExpress) follow the manufacturer’s instructions. .. Positive clones were selected in puromycin (Gibco)-containing medium.

    Article Title: ACSS2/AATF Drives Soluble FasL‐Mediated CD8 + T Cell Apoptosis in Pancreatic Neuroendocrine Tumors
    Article Snippet: .. Dimethyl sulfoxide (DMSO, D2650, Sigma–Aldrich), acetate (S8750, Sigma–Aldrich), ACSS2 inhibitor (ACSS2i, vy‐3‐135, #1824637‐41‐3, MedChemExpress), FasL blocking antibody (FasL antibody) (ab186671), animal‐free recombinant human soluble Fas ligand (rh‐sFasL, HY‐P700052AF, MedChemExpress), and Kp7‐6 (HY‐ P10102 , MedChemExpress) follow the manufacturer's instructions. .. Positive clones were selected in puromycin (Gibco)‐containing medium.

    Article Title: Tumor-infiltrated double-negative regulatory T cells predict outcome of T cell-based immunotherapy in nasopharyngeal carcinoma
    Article Snippet: .. REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Anti-human CD3 APC-CY7 BD Biosciences Cat#557757; RRID: AB_396863 CD4 Brilliant Violet 605TM Biolegend Cat#317438; RRID: AB_11218995 CD8 Brilliant Violet 650TM Biolegend Cat#344730; RRID: AB_2564510 CTLA4 PE BD Biosciences Cat#555853; RRID: AB_396176 FOXP3 BB700 BD Biosciences Cat#566526; RRID: AB_2744476 IKZF2 FITC Biolegend Cat#137214; RRID: AB_10662745 TGFβ BV421 BD Biosciences Cat#562962; RRID: AB_2737919 IL10 BV786 BD Biosciences Cat#564049; RRID: AB_2738563 Biological samples Pretreatment tumor tissue from TIL treatment trials (NCT02421640) This paper N/A Pretreatment PBMC from TIL treatment trials (NCT02421640) This paper N/A TIL infusion products from TIL treatment trials (NCT02421640) This paper N/A Healthy donor PBMC This paper N/A Chemicals, peptides, and recombinant proteins TGF-β neutralizing antibody Sanyou Biopharmaceuticals Cat#CHB215 IL-10 neutralizing antibody Sanyou Biopharmaceuticals Cat#CHA915 Fas-FasL signaling antagonist MedChemExpress CatHY-P10102 Anti-CD137 antibody Sanyou Biopharmaceuticals Cat#CHA103 Anti-CD30 antibody Sanyou Biopharmaceuticals Cat#CHA021 GITR inhibitor KKL Med Lnc Cat#KM2426 LDH Cytotoxicity Assay Kit Beyotime Cat#C0017 Anti-human CD3 monoclonal antibody (OKT3) R&D Systems Cat#GMP-A018-50 Recombinant human IFN-γ Biolegend Cat#570216 Recombinant human IL-2 Beijing Sihuan Pharm Cat#ss009 Recombinant human IL-1 alpha Life Technologies Cat#AHC0419 Phosphate buffered saline (PBS) Gibco Cat#C10010500BT X-Vivo LONZA Cat#04-418Q Collagenase IV Sigma-Aldrich Cat#C5138-100MG Deposited data Raw and analyzed bulk RNA sequencing data (human) This paper GSA-Human: HRA008590 Human TIL infusion products single cell RNA sequencing data This paper GSA-Human: HRA008590 Human TIL infusion products single cell RNA and TCR sequencing data This paper GSA-Human: HRA008590 Tumor and PBMC single cell RNA sequencing expression data Liu et al.38 GEO: GSE162025 Experimental models: Cell lines HEK293T Zhang et al.55 N/A LCL-N15 Xu et al.56 N/A TW03 Zhang et al.55 N/A TW03-EBV Zhang et al.55 N/A Software and algorithms FlowJo FlowJo https://www.flowjo.com/ R The R Project for Statistical Computing https://www.r-project.org/ Seurat package for R Hao et al.57 https://satijalab.org/seurat/ clusterProfiler package for R Wu et al.58 https://www.R-project.org/ (Continued on next page) Cell Reports Medicine 6, 102096, May 20, 2025 e1 Article ll OPEN ACCESS ..

    LDH Cytotoxicity Assay:

    Article Title: Tumor-infiltrated double-negative regulatory T cells predict outcome of T cell-based immunotherapy in nasopharyngeal carcinoma
    Article Snippet: .. REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Anti-human CD3 APC-CY7 BD Biosciences Cat#557757; RRID: AB_396863 CD4 Brilliant Violet 605TM Biolegend Cat#317438; RRID: AB_11218995 CD8 Brilliant Violet 650TM Biolegend Cat#344730; RRID: AB_2564510 CTLA4 PE BD Biosciences Cat#555853; RRID: AB_396176 FOXP3 BB700 BD Biosciences Cat#566526; RRID: AB_2744476 IKZF2 FITC Biolegend Cat#137214; RRID: AB_10662745 TGFβ BV421 BD Biosciences Cat#562962; RRID: AB_2737919 IL10 BV786 BD Biosciences Cat#564049; RRID: AB_2738563 Biological samples Pretreatment tumor tissue from TIL treatment trials (NCT02421640) This paper N/A Pretreatment PBMC from TIL treatment trials (NCT02421640) This paper N/A TIL infusion products from TIL treatment trials (NCT02421640) This paper N/A Healthy donor PBMC This paper N/A Chemicals, peptides, and recombinant proteins TGF-β neutralizing antibody Sanyou Biopharmaceuticals Cat#CHB215 IL-10 neutralizing antibody Sanyou Biopharmaceuticals Cat#CHA915 Fas-FasL signaling antagonist MedChemExpress CatHY-P10102 Anti-CD137 antibody Sanyou Biopharmaceuticals Cat#CHA103 Anti-CD30 antibody Sanyou Biopharmaceuticals Cat#CHA021 GITR inhibitor KKL Med Lnc Cat#KM2426 LDH Cytotoxicity Assay Kit Beyotime Cat#C0017 Anti-human CD3 monoclonal antibody (OKT3) R&D Systems Cat#GMP-A018-50 Recombinant human IFN-γ Biolegend Cat#570216 Recombinant human IL-2 Beijing Sihuan Pharm Cat#ss009 Recombinant human IL-1 alpha Life Technologies Cat#AHC0419 Phosphate buffered saline (PBS) Gibco Cat#C10010500BT X-Vivo LONZA Cat#04-418Q Collagenase IV Sigma-Aldrich Cat#C5138-100MG Deposited data Raw and analyzed bulk RNA sequencing data (human) This paper GSA-Human: HRA008590 Human TIL infusion products single cell RNA sequencing data This paper GSA-Human: HRA008590 Human TIL infusion products single cell RNA and TCR sequencing data This paper GSA-Human: HRA008590 Tumor and PBMC single cell RNA sequencing expression data Liu et al.38 GEO: GSE162025 Experimental models: Cell lines HEK293T Zhang et al.55 N/A LCL-N15 Xu et al.56 N/A TW03 Zhang et al.55 N/A TW03-EBV Zhang et al.55 N/A Software and algorithms FlowJo FlowJo https://www.flowjo.com/ R The R Project for Statistical Computing https://www.r-project.org/ Seurat package for R Hao et al.57 https://satijalab.org/seurat/ clusterProfiler package for R Wu et al.58 https://www.R-project.org/ (Continued on next page) Cell Reports Medicine 6, 102096, May 20, 2025 e1 Article ll OPEN ACCESS ..

    Saline:

    Article Title: Tumor-infiltrated double-negative regulatory T cells predict outcome of T cell-based immunotherapy in nasopharyngeal carcinoma
    Article Snippet: .. REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Anti-human CD3 APC-CY7 BD Biosciences Cat#557757; RRID: AB_396863 CD4 Brilliant Violet 605TM Biolegend Cat#317438; RRID: AB_11218995 CD8 Brilliant Violet 650TM Biolegend Cat#344730; RRID: AB_2564510 CTLA4 PE BD Biosciences Cat#555853; RRID: AB_396176 FOXP3 BB700 BD Biosciences Cat#566526; RRID: AB_2744476 IKZF2 FITC Biolegend Cat#137214; RRID: AB_10662745 TGFβ BV421 BD Biosciences Cat#562962; RRID: AB_2737919 IL10 BV786 BD Biosciences Cat#564049; RRID: AB_2738563 Biological samples Pretreatment tumor tissue from TIL treatment trials (NCT02421640) This paper N/A Pretreatment PBMC from TIL treatment trials (NCT02421640) This paper N/A TIL infusion products from TIL treatment trials (NCT02421640) This paper N/A Healthy donor PBMC This paper N/A Chemicals, peptides, and recombinant proteins TGF-β neutralizing antibody Sanyou Biopharmaceuticals Cat#CHB215 IL-10 neutralizing antibody Sanyou Biopharmaceuticals Cat#CHA915 Fas-FasL signaling antagonist MedChemExpress CatHY-P10102 Anti-CD137 antibody Sanyou Biopharmaceuticals Cat#CHA103 Anti-CD30 antibody Sanyou Biopharmaceuticals Cat#CHA021 GITR inhibitor KKL Med Lnc Cat#KM2426 LDH Cytotoxicity Assay Kit Beyotime Cat#C0017 Anti-human CD3 monoclonal antibody (OKT3) R&D Systems Cat#GMP-A018-50 Recombinant human IFN-γ Biolegend Cat#570216 Recombinant human IL-2 Beijing Sihuan Pharm Cat#ss009 Recombinant human IL-1 alpha Life Technologies Cat#AHC0419 Phosphate buffered saline (PBS) Gibco Cat#C10010500BT X-Vivo LONZA Cat#04-418Q Collagenase IV Sigma-Aldrich Cat#C5138-100MG Deposited data Raw and analyzed bulk RNA sequencing data (human) This paper GSA-Human: HRA008590 Human TIL infusion products single cell RNA sequencing data This paper GSA-Human: HRA008590 Human TIL infusion products single cell RNA and TCR sequencing data This paper GSA-Human: HRA008590 Tumor and PBMC single cell RNA sequencing expression data Liu et al.38 GEO: GSE162025 Experimental models: Cell lines HEK293T Zhang et al.55 N/A LCL-N15 Xu et al.56 N/A TW03 Zhang et al.55 N/A TW03-EBV Zhang et al.55 N/A Software and algorithms FlowJo FlowJo https://www.flowjo.com/ R The R Project for Statistical Computing https://www.r-project.org/ Seurat package for R Hao et al.57 https://satijalab.org/seurat/ clusterProfiler package for R Wu et al.58 https://www.R-project.org/ (Continued on next page) Cell Reports Medicine 6, 102096, May 20, 2025 e1 Article ll OPEN ACCESS ..

    RNA Sequencing:

    Article Title: Tumor-infiltrated double-negative regulatory T cells predict outcome of T cell-based immunotherapy in nasopharyngeal carcinoma
    Article Snippet: .. REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Anti-human CD3 APC-CY7 BD Biosciences Cat#557757; RRID: AB_396863 CD4 Brilliant Violet 605TM Biolegend Cat#317438; RRID: AB_11218995 CD8 Brilliant Violet 650TM Biolegend Cat#344730; RRID: AB_2564510 CTLA4 PE BD Biosciences Cat#555853; RRID: AB_396176 FOXP3 BB700 BD Biosciences Cat#566526; RRID: AB_2744476 IKZF2 FITC Biolegend Cat#137214; RRID: AB_10662745 TGFβ BV421 BD Biosciences Cat#562962; RRID: AB_2737919 IL10 BV786 BD Biosciences Cat#564049; RRID: AB_2738563 Biological samples Pretreatment tumor tissue from TIL treatment trials (NCT02421640) This paper N/A Pretreatment PBMC from TIL treatment trials (NCT02421640) This paper N/A TIL infusion products from TIL treatment trials (NCT02421640) This paper N/A Healthy donor PBMC This paper N/A Chemicals, peptides, and recombinant proteins TGF-β neutralizing antibody Sanyou Biopharmaceuticals Cat#CHB215 IL-10 neutralizing antibody Sanyou Biopharmaceuticals Cat#CHA915 Fas-FasL signaling antagonist MedChemExpress CatHY-P10102 Anti-CD137 antibody Sanyou Biopharmaceuticals Cat#CHA103 Anti-CD30 antibody Sanyou Biopharmaceuticals Cat#CHA021 GITR inhibitor KKL Med Lnc Cat#KM2426 LDH Cytotoxicity Assay Kit Beyotime Cat#C0017 Anti-human CD3 monoclonal antibody (OKT3) R&D Systems Cat#GMP-A018-50 Recombinant human IFN-γ Biolegend Cat#570216 Recombinant human IL-2 Beijing Sihuan Pharm Cat#ss009 Recombinant human IL-1 alpha Life Technologies Cat#AHC0419 Phosphate buffered saline (PBS) Gibco Cat#C10010500BT X-Vivo LONZA Cat#04-418Q Collagenase IV Sigma-Aldrich Cat#C5138-100MG Deposited data Raw and analyzed bulk RNA sequencing data (human) This paper GSA-Human: HRA008590 Human TIL infusion products single cell RNA sequencing data This paper GSA-Human: HRA008590 Human TIL infusion products single cell RNA and TCR sequencing data This paper GSA-Human: HRA008590 Tumor and PBMC single cell RNA sequencing expression data Liu et al.38 GEO: GSE162025 Experimental models: Cell lines HEK293T Zhang et al.55 N/A LCL-N15 Xu et al.56 N/A TW03 Zhang et al.55 N/A TW03-EBV Zhang et al.55 N/A Software and algorithms FlowJo FlowJo https://www.flowjo.com/ R The R Project for Statistical Computing https://www.r-project.org/ Seurat package for R Hao et al.57 https://satijalab.org/seurat/ clusterProfiler package for R Wu et al.58 https://www.R-project.org/ (Continued on next page) Cell Reports Medicine 6, 102096, May 20, 2025 e1 Article ll OPEN ACCESS ..

    Single Cell:

    Article Title: Tumor-infiltrated double-negative regulatory T cells predict outcome of T cell-based immunotherapy in nasopharyngeal carcinoma
    Article Snippet: .. REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Anti-human CD3 APC-CY7 BD Biosciences Cat#557757; RRID: AB_396863 CD4 Brilliant Violet 605TM Biolegend Cat#317438; RRID: AB_11218995 CD8 Brilliant Violet 650TM Biolegend Cat#344730; RRID: AB_2564510 CTLA4 PE BD Biosciences Cat#555853; RRID: AB_396176 FOXP3 BB700 BD Biosciences Cat#566526; RRID: AB_2744476 IKZF2 FITC Biolegend Cat#137214; RRID: AB_10662745 TGFβ BV421 BD Biosciences Cat#562962; RRID: AB_2737919 IL10 BV786 BD Biosciences Cat#564049; RRID: AB_2738563 Biological samples Pretreatment tumor tissue from TIL treatment trials (NCT02421640) This paper N/A Pretreatment PBMC from TIL treatment trials (NCT02421640) This paper N/A TIL infusion products from TIL treatment trials (NCT02421640) This paper N/A Healthy donor PBMC This paper N/A Chemicals, peptides, and recombinant proteins TGF-β neutralizing antibody Sanyou Biopharmaceuticals Cat#CHB215 IL-10 neutralizing antibody Sanyou Biopharmaceuticals Cat#CHA915 Fas-FasL signaling antagonist MedChemExpress CatHY-P10102 Anti-CD137 antibody Sanyou Biopharmaceuticals Cat#CHA103 Anti-CD30 antibody Sanyou Biopharmaceuticals Cat#CHA021 GITR inhibitor KKL Med Lnc Cat#KM2426 LDH Cytotoxicity Assay Kit Beyotime Cat#C0017 Anti-human CD3 monoclonal antibody (OKT3) R&D Systems Cat#GMP-A018-50 Recombinant human IFN-γ Biolegend Cat#570216 Recombinant human IL-2 Beijing Sihuan Pharm Cat#ss009 Recombinant human IL-1 alpha Life Technologies Cat#AHC0419 Phosphate buffered saline (PBS) Gibco Cat#C10010500BT X-Vivo LONZA Cat#04-418Q Collagenase IV Sigma-Aldrich Cat#C5138-100MG Deposited data Raw and analyzed bulk RNA sequencing data (human) This paper GSA-Human: HRA008590 Human TIL infusion products single cell RNA sequencing data This paper GSA-Human: HRA008590 Human TIL infusion products single cell RNA and TCR sequencing data This paper GSA-Human: HRA008590 Tumor and PBMC single cell RNA sequencing expression data Liu et al.38 GEO: GSE162025 Experimental models: Cell lines HEK293T Zhang et al.55 N/A LCL-N15 Xu et al.56 N/A TW03 Zhang et al.55 N/A TW03-EBV Zhang et al.55 N/A Software and algorithms FlowJo FlowJo https://www.flowjo.com/ R The R Project for Statistical Computing https://www.r-project.org/ Seurat package for R Hao et al.57 https://satijalab.org/seurat/ clusterProfiler package for R Wu et al.58 https://www.R-project.org/ (Continued on next page) Cell Reports Medicine 6, 102096, May 20, 2025 e1 Article ll OPEN ACCESS ..

    Sequencing:

    Article Title: Tumor-infiltrated double-negative regulatory T cells predict outcome of T cell-based immunotherapy in nasopharyngeal carcinoma
    Article Snippet: .. REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Anti-human CD3 APC-CY7 BD Biosciences Cat#557757; RRID: AB_396863 CD4 Brilliant Violet 605TM Biolegend Cat#317438; RRID: AB_11218995 CD8 Brilliant Violet 650TM Biolegend Cat#344730; RRID: AB_2564510 CTLA4 PE BD Biosciences Cat#555853; RRID: AB_396176 FOXP3 BB700 BD Biosciences Cat#566526; RRID: AB_2744476 IKZF2 FITC Biolegend Cat#137214; RRID: AB_10662745 TGFβ BV421 BD Biosciences Cat#562962; RRID: AB_2737919 IL10 BV786 BD Biosciences Cat#564049; RRID: AB_2738563 Biological samples Pretreatment tumor tissue from TIL treatment trials (NCT02421640) This paper N/A Pretreatment PBMC from TIL treatment trials (NCT02421640) This paper N/A TIL infusion products from TIL treatment trials (NCT02421640) This paper N/A Healthy donor PBMC This paper N/A Chemicals, peptides, and recombinant proteins TGF-β neutralizing antibody Sanyou Biopharmaceuticals Cat#CHB215 IL-10 neutralizing antibody Sanyou Biopharmaceuticals Cat#CHA915 Fas-FasL signaling antagonist MedChemExpress CatHY-P10102 Anti-CD137 antibody Sanyou Biopharmaceuticals Cat#CHA103 Anti-CD30 antibody Sanyou Biopharmaceuticals Cat#CHA021 GITR inhibitor KKL Med Lnc Cat#KM2426 LDH Cytotoxicity Assay Kit Beyotime Cat#C0017 Anti-human CD3 monoclonal antibody (OKT3) R&D Systems Cat#GMP-A018-50 Recombinant human IFN-γ Biolegend Cat#570216 Recombinant human IL-2 Beijing Sihuan Pharm Cat#ss009 Recombinant human IL-1 alpha Life Technologies Cat#AHC0419 Phosphate buffered saline (PBS) Gibco Cat#C10010500BT X-Vivo LONZA Cat#04-418Q Collagenase IV Sigma-Aldrich Cat#C5138-100MG Deposited data Raw and analyzed bulk RNA sequencing data (human) This paper GSA-Human: HRA008590 Human TIL infusion products single cell RNA sequencing data This paper GSA-Human: HRA008590 Human TIL infusion products single cell RNA and TCR sequencing data This paper GSA-Human: HRA008590 Tumor and PBMC single cell RNA sequencing expression data Liu et al.38 GEO: GSE162025 Experimental models: Cell lines HEK293T Zhang et al.55 N/A LCL-N15 Xu et al.56 N/A TW03 Zhang et al.55 N/A TW03-EBV Zhang et al.55 N/A Software and algorithms FlowJo FlowJo https://www.flowjo.com/ R The R Project for Statistical Computing https://www.r-project.org/ Seurat package for R Hao et al.57 https://satijalab.org/seurat/ clusterProfiler package for R Wu et al.58 https://www.R-project.org/ (Continued on next page) Cell Reports Medicine 6, 102096, May 20, 2025 e1 Article ll OPEN ACCESS ..

    Expressing:

    Article Title: Tumor-infiltrated double-negative regulatory T cells predict outcome of T cell-based immunotherapy in nasopharyngeal carcinoma
    Article Snippet: .. REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Anti-human CD3 APC-CY7 BD Biosciences Cat#557757; RRID: AB_396863 CD4 Brilliant Violet 605TM Biolegend Cat#317438; RRID: AB_11218995 CD8 Brilliant Violet 650TM Biolegend Cat#344730; RRID: AB_2564510 CTLA4 PE BD Biosciences Cat#555853; RRID: AB_396176 FOXP3 BB700 BD Biosciences Cat#566526; RRID: AB_2744476 IKZF2 FITC Biolegend Cat#137214; RRID: AB_10662745 TGFβ BV421 BD Biosciences Cat#562962; RRID: AB_2737919 IL10 BV786 BD Biosciences Cat#564049; RRID: AB_2738563 Biological samples Pretreatment tumor tissue from TIL treatment trials (NCT02421640) This paper N/A Pretreatment PBMC from TIL treatment trials (NCT02421640) This paper N/A TIL infusion products from TIL treatment trials (NCT02421640) This paper N/A Healthy donor PBMC This paper N/A Chemicals, peptides, and recombinant proteins TGF-β neutralizing antibody Sanyou Biopharmaceuticals Cat#CHB215 IL-10 neutralizing antibody Sanyou Biopharmaceuticals Cat#CHA915 Fas-FasL signaling antagonist MedChemExpress CatHY-P10102 Anti-CD137 antibody Sanyou Biopharmaceuticals Cat#CHA103 Anti-CD30 antibody Sanyou Biopharmaceuticals Cat#CHA021 GITR inhibitor KKL Med Lnc Cat#KM2426 LDH Cytotoxicity Assay Kit Beyotime Cat#C0017 Anti-human CD3 monoclonal antibody (OKT3) R&D Systems Cat#GMP-A018-50 Recombinant human IFN-γ Biolegend Cat#570216 Recombinant human IL-2 Beijing Sihuan Pharm Cat#ss009 Recombinant human IL-1 alpha Life Technologies Cat#AHC0419 Phosphate buffered saline (PBS) Gibco Cat#C10010500BT X-Vivo LONZA Cat#04-418Q Collagenase IV Sigma-Aldrich Cat#C5138-100MG Deposited data Raw and analyzed bulk RNA sequencing data (human) This paper GSA-Human: HRA008590 Human TIL infusion products single cell RNA sequencing data This paper GSA-Human: HRA008590 Human TIL infusion products single cell RNA and TCR sequencing data This paper GSA-Human: HRA008590 Tumor and PBMC single cell RNA sequencing expression data Liu et al.38 GEO: GSE162025 Experimental models: Cell lines HEK293T Zhang et al.55 N/A LCL-N15 Xu et al.56 N/A TW03 Zhang et al.55 N/A TW03-EBV Zhang et al.55 N/A Software and algorithms FlowJo FlowJo https://www.flowjo.com/ R The R Project for Statistical Computing https://www.r-project.org/ Seurat package for R Hao et al.57 https://satijalab.org/seurat/ clusterProfiler package for R Wu et al.58 https://www.R-project.org/ (Continued on next page) Cell Reports Medicine 6, 102096, May 20, 2025 e1 Article ll OPEN ACCESS ..

    Software:

    Article Title: Tumor-infiltrated double-negative regulatory T cells predict outcome of T cell-based immunotherapy in nasopharyngeal carcinoma
    Article Snippet: .. REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Anti-human CD3 APC-CY7 BD Biosciences Cat#557757; RRID: AB_396863 CD4 Brilliant Violet 605TM Biolegend Cat#317438; RRID: AB_11218995 CD8 Brilliant Violet 650TM Biolegend Cat#344730; RRID: AB_2564510 CTLA4 PE BD Biosciences Cat#555853; RRID: AB_396176 FOXP3 BB700 BD Biosciences Cat#566526; RRID: AB_2744476 IKZF2 FITC Biolegend Cat#137214; RRID: AB_10662745 TGFβ BV421 BD Biosciences Cat#562962; RRID: AB_2737919 IL10 BV786 BD Biosciences Cat#564049; RRID: AB_2738563 Biological samples Pretreatment tumor tissue from TIL treatment trials (NCT02421640) This paper N/A Pretreatment PBMC from TIL treatment trials (NCT02421640) This paper N/A TIL infusion products from TIL treatment trials (NCT02421640) This paper N/A Healthy donor PBMC This paper N/A Chemicals, peptides, and recombinant proteins TGF-β neutralizing antibody Sanyou Biopharmaceuticals Cat#CHB215 IL-10 neutralizing antibody Sanyou Biopharmaceuticals Cat#CHA915 Fas-FasL signaling antagonist MedChemExpress CatHY-P10102 Anti-CD137 antibody Sanyou Biopharmaceuticals Cat#CHA103 Anti-CD30 antibody Sanyou Biopharmaceuticals Cat#CHA021 GITR inhibitor KKL Med Lnc Cat#KM2426 LDH Cytotoxicity Assay Kit Beyotime Cat#C0017 Anti-human CD3 monoclonal antibody (OKT3) R&D Systems Cat#GMP-A018-50 Recombinant human IFN-γ Biolegend Cat#570216 Recombinant human IL-2 Beijing Sihuan Pharm Cat#ss009 Recombinant human IL-1 alpha Life Technologies Cat#AHC0419 Phosphate buffered saline (PBS) Gibco Cat#C10010500BT X-Vivo LONZA Cat#04-418Q Collagenase IV Sigma-Aldrich Cat#C5138-100MG Deposited data Raw and analyzed bulk RNA sequencing data (human) This paper GSA-Human: HRA008590 Human TIL infusion products single cell RNA sequencing data This paper GSA-Human: HRA008590 Human TIL infusion products single cell RNA and TCR sequencing data This paper GSA-Human: HRA008590 Tumor and PBMC single cell RNA sequencing expression data Liu et al.38 GEO: GSE162025 Experimental models: Cell lines HEK293T Zhang et al.55 N/A LCL-N15 Xu et al.56 N/A TW03 Zhang et al.55 N/A TW03-EBV Zhang et al.55 N/A Software and algorithms FlowJo FlowJo https://www.flowjo.com/ R The R Project for Statistical Computing https://www.r-project.org/ Seurat package for R Hao et al.57 https://satijalab.org/seurat/ clusterProfiler package for R Wu et al.58 https://www.R-project.org/ (Continued on next page) Cell Reports Medicine 6, 102096, May 20, 2025 e1 Article ll OPEN ACCESS ..



    Similar Products

    kp7 6  (MedChemExpress)
    93
    MedChemExpress kp7 6
    Kp7 6, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-p10102/Kp7-6/pmc12561415-47-30-34
    Average 93 stars, based on 1 article reviews
    kp7 6 - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    fas fasl signaling antagonist  (MedChemExpress)
    93
    MedChemExpress fas fasl signaling antagonist
    Associations of CD8 + TIL subsets with (DN) TILs and clinical outcome (A) Dot color represents the communication probability of the specific ligand-receptor pairs, including TGF-β, IL-10, <t>and</t> <t>Fas-FasL</t> signaling between the indicated sender cluster and receiver clusters. (B) Representative histograms and statistical graph showing carboxyfluorescein succinimidyl ester (CFSE) dilution (left) and proliferation inhibition rates (right) of (DN) TILs with CD4 + and CD8 + naive T cells at a ratio of 4:1, 2:1, 1:1, and 1:2. The data are presented as mean ± SD, and three biological replicates were included. (C) Representative histograms and statistical graph showing CFSE dilution (left) and proliferation inhibition rates (right) of (DN) TILs with CD4 + and CD8 + naive T cells at a 1:1 ratio with neutralizing antibodies against TGF-β and IL-10, as well as the presence or absence of a Fas-FasL signaling antagonist. The data are presented as mean ± SD, and three biological replicates were included. p values were evaluated by t test (two-sided). ∗∗ p < 0.01; ∗∗∗ p < 0.001. (D) Bubble plot showing the correlation between the frequency of (DN) TILs and other TIL subsets in TIL infusion products ( n = 26). p values were determined by Spearman correlation analysis. ∗ p < 0.05. (E) Dot plot showing the correlation between the frequency of (DN) TILs and CD8 + TILs in TIL infusion products ( n = 26). p values were determined by Spearman correlation analysis. (F) Representative histograms and statistical graph showing CFSE dilution (left) and proliferation inhibition rates (right) of (DN) TILs with autologous expanded CD8 + TILs at ratios of 4:1, 2:1, and 1:1. Conventional CD4 + (i)Tregs were included as a control. The data are presented as mean ± SD, and three biological replicates were included. (G–K) Kaplan-Meier survival curves of PFS and OS in NPC patients stratified according to the abundance (high vs. low) of total CD8 + TILs (G), C2_proliferation_CD8_T_cells-PCNA (H), C4_MHC_II_CD8_T_cells (I), C6_proliferation_CD8_T_cells-TOP2A (J), and C12_tissue_resident_memory_CD8_T_cells (K) inferred from (sc)RNA sequencing data ( n = 26). p values were determined based on the two-sided log rank test. See also and .
    Fas Fasl Signaling Antagonist, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-p10102/Kp7-6/pmc12147895-22-0-4
    Average 93 stars, based on 1 article reviews
    fas fasl signaling antagonist - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    fas fasl signaling antagonist medchemexpress cat  (MedChemExpress)
    93
    MedChemExpress fas fasl signaling antagonist medchemexpress cat
    Associations of CD8 + TIL subsets with (DN) TILs and clinical outcome (A) Dot color represents the communication probability of the specific ligand-receptor pairs, including TGF-β, IL-10, <t>and</t> <t>Fas-FasL</t> signaling between the indicated sender cluster and receiver clusters. (B) Representative histograms and statistical graph showing carboxyfluorescein succinimidyl ester (CFSE) dilution (left) and proliferation inhibition rates (right) of (DN) TILs with CD4 + and CD8 + naive T cells at a ratio of 4:1, 2:1, 1:1, and 1:2. The data are presented as mean ± SD, and three biological replicates were included. (C) Representative histograms and statistical graph showing CFSE dilution (left) and proliferation inhibition rates (right) of (DN) TILs with CD4 + and CD8 + naive T cells at a 1:1 ratio with neutralizing antibodies against TGF-β and IL-10, as well as the presence or absence of a Fas-FasL signaling antagonist. The data are presented as mean ± SD, and three biological replicates were included. p values were evaluated by t test (two-sided). ∗∗ p < 0.01; ∗∗∗ p < 0.001. (D) Bubble plot showing the correlation between the frequency of (DN) TILs and other TIL subsets in TIL infusion products ( n = 26). p values were determined by Spearman correlation analysis. ∗ p < 0.05. (E) Dot plot showing the correlation between the frequency of (DN) TILs and CD8 + TILs in TIL infusion products ( n = 26). p values were determined by Spearman correlation analysis. (F) Representative histograms and statistical graph showing CFSE dilution (left) and proliferation inhibition rates (right) of (DN) TILs with autologous expanded CD8 + TILs at ratios of 4:1, 2:1, and 1:1. Conventional CD4 + (i)Tregs were included as a control. The data are presented as mean ± SD, and three biological replicates were included. (G–K) Kaplan-Meier survival curves of PFS and OS in NPC patients stratified according to the abundance (high vs. low) of total CD8 + TILs (G), C2_proliferation_CD8_T_cells-PCNA (H), C4_MHC_II_CD8_T_cells (I), C6_proliferation_CD8_T_cells-TOP2A (J), and C12_tissue_resident_memory_CD8_T_cells (K) inferred from (sc)RNA sequencing data ( n = 26). p values were determined based on the two-sided log rank test. See also and .
    Fas Fasl Signaling Antagonist Medchemexpress Cat, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-p10102/Kp7-6/pmc12147895__mmc4-206-121-124
    Average 93 stars, based on 1 article reviews
    fas fasl signaling antagonist medchemexpress cat - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    kp7-6  (MedChemExpress)
    93
    MedChemExpress kp7-6
    Associations of CD8 + TIL subsets with (DN) TILs and clinical outcome (A) Dot color represents the communication probability of the specific ligand-receptor pairs, including TGF-β, IL-10, <t>and</t> <t>Fas-FasL</t> signaling between the indicated sender cluster and receiver clusters. (B) Representative histograms and statistical graph showing carboxyfluorescein succinimidyl ester (CFSE) dilution (left) and proliferation inhibition rates (right) of (DN) TILs with CD4 + and CD8 + naive T cells at a ratio of 4:1, 2:1, 1:1, and 1:2. The data are presented as mean ± SD, and three biological replicates were included. (C) Representative histograms and statistical graph showing CFSE dilution (left) and proliferation inhibition rates (right) of (DN) TILs with CD4 + and CD8 + naive T cells at a 1:1 ratio with neutralizing antibodies against TGF-β and IL-10, as well as the presence or absence of a Fas-FasL signaling antagonist. The data are presented as mean ± SD, and three biological replicates were included. p values were evaluated by t test (two-sided). ∗∗ p < 0.01; ∗∗∗ p < 0.001. (D) Bubble plot showing the correlation between the frequency of (DN) TILs and other TIL subsets in TIL infusion products ( n = 26). p values were determined by Spearman correlation analysis. ∗ p < 0.05. (E) Dot plot showing the correlation between the frequency of (DN) TILs and CD8 + TILs in TIL infusion products ( n = 26). p values were determined by Spearman correlation analysis. (F) Representative histograms and statistical graph showing CFSE dilution (left) and proliferation inhibition rates (right) of (DN) TILs with autologous expanded CD8 + TILs at ratios of 4:1, 2:1, and 1:1. Conventional CD4 + (i)Tregs were included as a control. The data are presented as mean ± SD, and three biological replicates were included. (G–K) Kaplan-Meier survival curves of PFS and OS in NPC patients stratified according to the abundance (high vs. low) of total CD8 + TILs (G), C2_proliferation_CD8_T_cells-PCNA (H), C4_MHC_II_CD8_T_cells (I), C6_proliferation_CD8_T_cells-TOP2A (J), and C12_tissue_resident_memory_CD8_T_cells (K) inferred from (sc)RNA sequencing data ( n = 26). p values were determined based on the two-sided log rank test. See also and .
    Kp7 6, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-p10102/Kp7-6/custom%40hy-p10102%4040315843
    Average 93 stars, based on 1 article reviews
    kp7-6 - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Associations of CD8 + TIL subsets with (DN) TILs and clinical outcome (A) Dot color represents the communication probability of the specific ligand-receptor pairs, including TGF-β, IL-10, and Fas-FasL signaling between the indicated sender cluster and receiver clusters. (B) Representative histograms and statistical graph showing carboxyfluorescein succinimidyl ester (CFSE) dilution (left) and proliferation inhibition rates (right) of (DN) TILs with CD4 + and CD8 + naive T cells at a ratio of 4:1, 2:1, 1:1, and 1:2. The data are presented as mean ± SD, and three biological replicates were included. (C) Representative histograms and statistical graph showing CFSE dilution (left) and proliferation inhibition rates (right) of (DN) TILs with CD4 + and CD8 + naive T cells at a 1:1 ratio with neutralizing antibodies against TGF-β and IL-10, as well as the presence or absence of a Fas-FasL signaling antagonist. The data are presented as mean ± SD, and three biological replicates were included. p values were evaluated by t test (two-sided). ∗∗ p < 0.01; ∗∗∗ p < 0.001. (D) Bubble plot showing the correlation between the frequency of (DN) TILs and other TIL subsets in TIL infusion products ( n = 26). p values were determined by Spearman correlation analysis. ∗ p < 0.05. (E) Dot plot showing the correlation between the frequency of (DN) TILs and CD8 + TILs in TIL infusion products ( n = 26). p values were determined by Spearman correlation analysis. (F) Representative histograms and statistical graph showing CFSE dilution (left) and proliferation inhibition rates (right) of (DN) TILs with autologous expanded CD8 + TILs at ratios of 4:1, 2:1, and 1:1. Conventional CD4 + (i)Tregs were included as a control. The data are presented as mean ± SD, and three biological replicates were included. (G–K) Kaplan-Meier survival curves of PFS and OS in NPC patients stratified according to the abundance (high vs. low) of total CD8 + TILs (G), C2_proliferation_CD8_T_cells-PCNA (H), C4_MHC_II_CD8_T_cells (I), C6_proliferation_CD8_T_cells-TOP2A (J), and C12_tissue_resident_memory_CD8_T_cells (K) inferred from (sc)RNA sequencing data ( n = 26). p values were determined based on the two-sided log rank test. See also and .

    Journal: Cell Reports Medicine

    Article Title: Tumor-infiltrated double-negative regulatory T cells predict outcome of T cell-based immunotherapy in nasopharyngeal carcinoma

    doi: 10.1016/j.xcrm.2025.102096

    Figure Lengend Snippet: Associations of CD8 + TIL subsets with (DN) TILs and clinical outcome (A) Dot color represents the communication probability of the specific ligand-receptor pairs, including TGF-β, IL-10, and Fas-FasL signaling between the indicated sender cluster and receiver clusters. (B) Representative histograms and statistical graph showing carboxyfluorescein succinimidyl ester (CFSE) dilution (left) and proliferation inhibition rates (right) of (DN) TILs with CD4 + and CD8 + naive T cells at a ratio of 4:1, 2:1, 1:1, and 1:2. The data are presented as mean ± SD, and three biological replicates were included. (C) Representative histograms and statistical graph showing CFSE dilution (left) and proliferation inhibition rates (right) of (DN) TILs with CD4 + and CD8 + naive T cells at a 1:1 ratio with neutralizing antibodies against TGF-β and IL-10, as well as the presence or absence of a Fas-FasL signaling antagonist. The data are presented as mean ± SD, and three biological replicates were included. p values were evaluated by t test (two-sided). ∗∗ p < 0.01; ∗∗∗ p < 0.001. (D) Bubble plot showing the correlation between the frequency of (DN) TILs and other TIL subsets in TIL infusion products ( n = 26). p values were determined by Spearman correlation analysis. ∗ p < 0.05. (E) Dot plot showing the correlation between the frequency of (DN) TILs and CD8 + TILs in TIL infusion products ( n = 26). p values were determined by Spearman correlation analysis. (F) Representative histograms and statistical graph showing CFSE dilution (left) and proliferation inhibition rates (right) of (DN) TILs with autologous expanded CD8 + TILs at ratios of 4:1, 2:1, and 1:1. Conventional CD4 + (i)Tregs were included as a control. The data are presented as mean ± SD, and three biological replicates were included. (G–K) Kaplan-Meier survival curves of PFS and OS in NPC patients stratified according to the abundance (high vs. low) of total CD8 + TILs (G), C2_proliferation_CD8_T_cells-PCNA (H), C4_MHC_II_CD8_T_cells (I), C6_proliferation_CD8_T_cells-TOP2A (J), and C12_tissue_resident_memory_CD8_T_cells (K) inferred from (sc)RNA sequencing data ( n = 26). p values were determined based on the two-sided log rank test. See also and .

    Article Snippet: Fas-FasL signaling antagonist , MedChemExpress , Cat#HY- P10102.

    Techniques: Inhibition, Control, RNA Sequencing